Clinical stage company developing an orally administered compound to inhibit the dysregulated NLRP3 Inflammasome pathway of autoinflammation.
Indications: Diabetic Macular Edema (DME) secondary to Diabetic Retinopathy (DR), Chronic Kidney Disease secondary to Diabetic Nephropathy (DN) and the Intermediate form of Age Related Macular Degeneration (AMD).
Phase 2 asset (Xiflam) planning to be in clinical trials in 2022. Patients will be dosed once a day with Xiflam or Placebo tablets.
The objective of InflammX technology is disease modification through inhibiting the dysregulated NLRP3 Inflammasome by normalizing pathological prematurely open hemichannels in the cell membrane. These pathologically open Cx43 hemichannels release ATP into the extracellular space which is a signal for activation of the NLRP3 Inflammasome and release of multiple proinflammatory cytokines. This results in perpetuated autoinflammation in the clinically indicated diseases mentioned above. Xiflam has been shown to inhibit the pathologically open hemichannels resulting in reduced inflammation and tissue regeneration. in phenotypical models of the disease. Peer reviewed literature on the inflammasome supports the Cx43 mechanism as an activator of the NLRP3 inflammasome and drugs such as Xiflam being effective in multiple disease states.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Tampa, Fl 33606, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://inflammx.com
- Keywords
- biopharmaceuticals, Diabetic Retinopathy, Diabetic Nephropathy, Intermediate form of Age Related macular Degeneration (iAMD).
- HQ
- Tampa, FL
Inflammx Therapeutics, Inc. Questions
Inflammx Therapeutics, Inc.'s website is http://inflammx.com
Inflammx Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/inflammx
Inflammx Therapeutics, Inc. has
4 employees.
View email and phone details for 4
employees at Inflammx Therapeutics, Inc..
Inflammx Therapeutics, Inc.'s industry is
Pharmaceutical Manufacturing
Inflammx Therapeutics, Inc.'s top competitors are
Opus Genetics,
Regenxbio,
Nacuity Pharmaceuticals, Inc.,
Exsight Ventures,
Inhibitor Therapeutics, Inc.,
Bausch + Lomb,
Character Biosciences,
Optigo Biotherapeutics,
Cyrano Therapeutics,
Sightstream Biotherapeutics.
Inflammx Therapeutics, Inc.'s categories are Pharmaceutical Manufacturing
Inflammx Therapeutics, Inc.'s founding year is 2020
